When Should Levodopa Therapy be Initiated in Patients with Parkinson’s Disease?

被引：0
作者：
Irene A. C. Halkias
Ihtsham Haq
Zhigao Huang
Hubert H. Fernandez
机构：
[1] University of Florida,Department of Neurology
来源：
Drugs & Aging | 2007年 / 24卷
关键词：
Levodopa; Pramipexole; Ropinirole; Entacapone; Motor Fluctuation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Levodopa is available in three forms: immediate-release, orally disintegrating and sustained-release tablets. Levodopa is metabolised in the gastrointestinal tract, kidney and liver by aromatic acid dopa decarboxylase using pyridoxine as a cofactor. Approximately 70–80% of the dose is eliminated in the urine. Central conversion of levodopa to dopamine likely occurs at surviving dopaminergic terminals and at serotonergic and adrenergic nerve terminals that contain decarboxylase. Dopamine is metabolised by catechol-O-methyltransferase and monoamine oxidase. The major metabolites of dopamine are homovanillic acid and dihydroxyphenylacetic acid.
引用
收藏
页码：261 / 273
页数：12
相关论文
共 178 条
  • [1] Ehringer H(1960)Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin Wochenschr 38 1236-9
  • [2] Hornykiewicz O(1961)The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia Wien Klin Wochenschr 73 787-8
  • [3] Birkmayer W(1968)L-Dopa for Parkinsonism N Engl J Med 278 630-9
  • [4] Hornykiewicz O(1967)Aromatic amino acids and modification of parkinsonism N Engl J Med 276 374-10
  • [5] Cotzias GC(1998)History of levodopa and dopamine agonists in Parkinson’s disease treatment Neurology 50 S2-45
  • [6] Cotzias GC(1969)Modification of Parkinsonism: chronic treatment with L-dopa N Engl J Med 280 337-206
  • [7] Van Woert MH(1974)Parkinson’s disease and levodopa: a five-year follow-up and review West J Med 121 188-56
  • [8] Schiffer LM(2004)Levodopa infusion therapy in Parkinson disease: state of the art in 2004 Clin Neuropharmacol 27 245-9
  • [9] Tolosa E(1990)Pharmacokinetics and effects of levodopa in advanced Parkinson’s disease Eur J Clin Pharmacol 39 385-61
  • [10] Marti MJ(2002)Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson’s disease patients experiencing motor fluctuations with levodopa J Pharm Pharm Sci 5 146-8
12345678910